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Background: Eosinophilic granulomatosis with polyangiitis is a complex multisystemic syndrome with heterogeneous
presentation. Most often, there is a clinical history of asthma or other atopic conditions, and current presentation
generally includes signs of cutaneous or pulmonary involvement. Very few reports described myalgia or weakness as
the chief complaint. Of these, only a few included muscle biopsy evaluation and none showed convincing evidence of
primary myositis. We believe this report is the first to demonstrate true myositis in the setting of early eosinophilic
granulomatosis with polyangiitis.
Case presentation: This report describes a 74 year old Caucasian man, with no known allergies, presenting severe
myalgia, muscle weakness, jaw claudication, and fever. Blood work showed marked eosinophilia and high creatine
kinase levels. Biceps brachialis muscle biopsy revealed eosinophilic necrotizing vasculitis and true myositis with
myophagocytosis of non-necrotic fibers and strong sarcolemmal MHC-1 overexpression by immunohistochemistry. This
patient was successfully treated with prednisone and azathioprine.
Conclusion: Our finding of true myositis in a case of eosinophilic granulomatosis with polyangiitis suggests that
primary auto-immunity against muscle fibers, distinct from the secondary effects of vasculitis, can occur in this entity
and may represent an overlap syndrome. Early recognition of eosinophilic granulomatosis with polyangiitis in patients
presenting with myositis may provide an opportunity to treat the vasculitis before onset of severe multisystemic
disease. We recommend the use of muscle biopsy with immunohistochemistry for MHC-1 to confirm the diagnosis
of myositis in the setting of eosinophilic granulomatosis with polyangiitis.
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In 1951, Churg and Strauss [1] described a syndrome with
a relatively uniform clinical picture of severe asthma, fever,
peripheral eosinophilia, and symptoms of “vascular em-
barrassment” in 13 patients initially diagnosed as having
polyarteritis nodosa. Churg-Strauss syndrome (CSS) or
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
is an uncommon form of antineutrophil cytoplasmic
antibody-associated necrotizing vasculitis affecting the
small-to-medium sized blood vessels. Disease typically fol-
lows three phases. The prodromal phase presents as adult-
onset asthma, atopic disease, and allergic rhinosinusitis. It* Correspondence: Marc-Etienne.Parent@USherbrooke.ca
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unless otherwise stated.precedes the vasculitic phase by 3 to 9 years but intervals
as long as 30 years have also been described [2]. Next, is
the eosinophilic phase which is usually a subclinical eo-
sinophilic tissue infiltration without necrosis but can some-
times manifest as pulmonary infiltrates or nodules with or
without pneumonitis, or as gastroenteritis [3,4]. The third
and final phase is the vasculitic phase, where patients are
usually diagnosed. The mean age at presentation varies
from 38 to 52 years of age, but can range from 7 to 74
[2,5]. In a recent large systematic retrospective study of
383 patients with EGPA [5], the most common manifesta-
tions at the time of diagnosis were asthma (91.1%), weight
loss (49.3%), mononeuritis multiplex (46%), sinusitis or
polyposis (41.8%), skin lesions (39.7%), and lung infiltrates
(38.6%). In another study and follow-up of 96 patients [3],
94 had asthma at presentation and the remaining 2Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A history of allergy is less common when compared to
asthma, being described in only 27.2% of patients at pres-
entation [3].
Other than eosinophilia, laboratory data is usually
nonspecific and of little help in establishing the diagno-
sis of EGPA. Eosinophilia usually appears in the second
phase of disease, but can also initially present in the pro-
dromal or vasculitic phases [6]. Reported mean levels
are 7–8 ×109/L [3,4]. Interestingly in these studies, some
patients had blood eosinophil counts of <0.5 ×109/L at
the time of diagnosis, but all were already taking oral CS
for asthma control. Similarly, in the Guillevin et al. [3]
follow-up, 10 patients had a blood eosinophilia count
<1.5 ×109/L, but all were >0.5 ×109/L. Eight of these pa-
tients were also already on oral CS. The presence of
ANCA is documented in approximately 40% of EGPA
[2-5,7] and appears to be associated with renal and upper
respiratory tract involvement, alveolar hemorrhage, pur-
pura, biopsy-proven vasculitis and peripheral neuropathy.
The absence of ANCA is associated with pulmonary dis-
ease, cardiomyopathy, and fever [2,3,8]. The origin of this
dichotomy is uncertain but it is hypothesized that the tis-
sue damage in ANCA-negative EGPA is directly related to
the presence of tissue eosinophils, whereas the ANCA-
positive patients are thought to have endothelial damage
in the typical ANCA-associated vasculitis fashion [2].
In 1990, the American College of Rheumatology estab-
lished the classification criteria for EGPA with a sensitiv-
ity of 85% and specificity of 99.7% [9]. It is important to
keep in mind that these criteria were established to dif-
ferentiate patients with EGPA from patients with other
forms of vasculitis. Hence, their use in absence of biopsy-
proven vasculitis is of little help. Fulfillment of 4 or more
criteria is needed for classification as EGPA. The criteria
are (1) asthma, (2) eosinophilia greater than 10% on differ-
ential white blood cell count, (3) mononeuropathy or
polyneuropathy, (4) migratory or transient pulmonary in-
filtrates detected radiographically, (5) paranasal sinus ab-
normality, and (6) biopsy with perivascular eosinophils.
Myalgia can be a common symptom of EGPA and has
been observed in up to 37-57% of cases of EGPA [2,3,5].
However, it is rarely seen as the main presenting symp-
tom and is more commonly observed in the prodromal
phase of disease [2,8] and not typically associated with
weakness [3]. It is sometimes accompanied by migratory
polyarthralgia although true arthritis is uncommon. In
one study, myalgia did not correlate with ANCA status
[5]. Unfortunately, CK levels have not been reported in
EGPA case series.
Very few EGPA cases of patients having myalgia and
weakness as the main presenting complaints have been
reported to date. Muscle biopsy descriptions are limited
and reveal only vasculitis rather than usual features ofprimary inflammatory myopathy that would be expected
in a true “myositis”, such as phagocytosis of non-necrotic
fibers, dense endomysial or perimysial lymphocytic infil-
trates, or sarcolemmal overexpression of MHC-1. One pa-
tient was a 68 year old woman with a long history of
sinusitis and more recent onset asthma presenting with
myalgia, mild leg weakness, and elevated CK following
strenuous exercise [10]. However, muscle biopsy only
showed vasculitis and eosinophilic infiltration but no fur-
ther inflammatory myopathic features. Another was an
81 year old man with late onset asthma, presenting with a
3-week history of myalgia and weakness with mild CK ele-
vation, reduced nerve conduction amplitudes, and normal
EMG [11]. Muscle biopsy showed necrotizing vasculitis
with eosinophils in an epimysial medium-sized artery but
no endomysial inflammation. Angulated atrophic fibers
were present, a histologic sign of denervation. A third re-
port described a 58 year old woman, again with late onset
asthma, who presented with a 5-month history of progres-
sive exercise-induced muscle weakness, stiffness and pain,
and evidence of axonal neuropathy on electrophysiologic
studies. Muscle biopsy revealed necrotizing vasculitis of
medium-sized arteries and an extra-vascular granuloma,
both associated with eosinophils. Some focal interstitial in-
filtration with eosinophils was present but no features of
inflammatory myopathy were reported [12]. In a retro-
spective single center study of 19 patients with EGPA, 10
patients were documented as having myalgia but only one
underwent biopsy, reported as showing “myositis” with no
further histologic description or immunohistochemical
analysis to support it [13].
Case presentation
A 74 year old Caucasian man presented to the emer-
gency room complaining of severe diffuse myalgia, motor
fatigability with jaw claudication, a 7-day fever, and a sin-
gle episode of hemoptysis preceded by increasingly fre-
quent cold-induced paroxysmal dyspnea. Despite being a
smoker, he reported only two previous episodes of severe
dyspnea with audible wheezing and mild productive cough
in the two years prior, both treated with bronchodilators
or a short course of CS plus antibiotics. Spirometry dem-
onstrated mild airway obstruction with partial reversibility.
There were no drug use or known allergies but he re-
ported a 20-year history of recurrent rhinorrhea and
chronic nasal obstruction. History was also remarkable for
consumption of bear meat during recent hunting trips
within Canada and the United States, but negative for car-
diopulmonary, cutaneous, or neurological symptoms such
as paresthesia or sensory deficits.
On examination, blood pressure was 117/72 mmHg,
heart rate 103 beats/minute, and oral temperature 38.0°
C. There was a 2/6 systolic murmur over mitral and aor-
tic areas with radiation to both carotids and the left
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psoas muscles, 4/5 weakness in upper and lower limbs,
and diffuse bilateral myalgia. Sensitivity, tone and reflexes
were normal. Examination was otherwise unremarkable.
Laboratory values revealed mild leukocytosis, 18.5 ×109/L
(N, 4.5-11.3 ×109/L); marked eosinophilia, 5.07 ×109/L
(N, <0.80 ×109/L); hyperCKemia, 3708 U/L (N 15–195 U/
L); increased C-reactive protein, 173.7 mg/L (N, <5.0 mg/L);
increased rheumatoid factor, 77 kU/L (N, <14 kU/L);
increased alkaline phosphatase, 235 U/L (N, 30–105 U/L),
and slightly increased alanine transaminase, 86 U/L
(normal, 5–55 U/L); Complement C3 and C4 were nor-
mal. Myeloperoxidase-specific antineutrophil cytoplasmic
antibody (MPO-ANCA), antinuclear antigen (ANA), and
cytoplasmic-staining antineutrophil cytoplasmic antibody
(C-ANCA) were negative. Serum protein electrophoresis
showed a non-specific reactive pattern. Blood, stool, and
urine cultures including testing for parasites were nega-
tive. Serology for trichinellosis, HIV, HBV, HCV, and
CMV were negative, as was EBV monotest. PPD skin test
was non-reactive.
Chest x-ray, abdominal ultrasound, and electrocardio-
gram were normal. Transthoracic cardiac ultrasound
showed mild aortic stenosis, mild mitral stenosis, and
mild to moderate mitral regurgitation. There was no evi-
dence of endocarditis. Head CT scan showed sinusitisFigure 1 Histopathologic evidence of vasculitis, neurogenic atrophy,
necrotizing vasculitis of medium-sized artery with abundant eosinophils; B,
necrotic fibers; D, phagocytosis of non-necrotic fiber; and E, fiber with rimm
sarcolemmal and sarcoplasmic expression. Bar (in A, mm): A, 0.1; B, 0.2; C, 0with mucus infiltration of the frontal and maxillary si-
nuses. Thoracic CT scan showed multiple centrilobular
micronodules bilaterally, predominantly in the upper lobes,
7 mm in maximum diameter. Magnetic resonance imaging
(MRI) of the lower body showed mild muscular atrophy
with diffuse hypersignal in STIR sequence. Electrophysio-
logic studies demonstrated preserved motor and sensory
conductions in all four limbs. Extensive needle elec-
tromyography revealed increased insertional activity,
abundant fibrillations with positive sharp waves, and no
fasciculations. A clear myopathic recruitment pattern
was also found in proximal and distal muscles.
Muscle biopsy from the left biceps brachialis (which
showed intermediate involvement clinically) was per-
formed before treatment with steroids and revealed
eosinophil-rich necrotizing vasculitis in perimysial blood
vessels (Figure 1A). There were no granulomas or endo-
mysial eosinophilic infiltrates. Most prominent was the
presence of atrophic angulated or split fibers, internal-
ized nuclei, nuclear clumps, grouped atrophy, and foci of
endomysial fibrosis (Figure 1B). Some fascicles showed
isolated necrotic fibers (Figure 1C), phagocytosis of non-
necrotic fibers (Figure 1D), or fibers with rimmed vacuoles
(Figure 1E), but no perifascicular atrophy was seen and lit-
tle inflammation was present outside areas of vasculitis.
By immunohistochemistry, MHC-1 was overexpressed inand myositis. A-E (HES stain), muscle cryostat sections showing: A,
atrophic angulated fibers, nuclear clumps, and split fibers; C, isolated
ed vacuole. F, MHC-1 immunohistochemical stain showing variable
.18; D, 0.12; E, 0.07; F, 0.4.
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culitis (Figure 1 F). Membrane attack complex (C5b9) was
negative in endomysial capillaries (not shown). The lympho-
cytic infiltrate showed CD3:CD20 and CD4:CD8 ratios
close to 1 (not shown). Apart from the vasculitis, the muscle
biopsy was interpreted as consistent with chronic partial
denervation with histologic and immunohistochemical evi-
dence of nonspecific inflammatory myopathy.
After a few days in the hospital, fever subsided spontan-
eously and myalgia improved slightly with rest. Prednisone
80 mg and azathioprine 50 mg daily were introduced at
discharge with tapering of 10 mg every 14 days. Within
2 weeks, laboratory data showed: white blood cell count,
17.0 ×109/L; eosinophil count, 0.11 ×109/L; creatine kinase
(CK), 63 U/L; C-reactive protein, 6.9 mg/L and alanine
transaminase, 32 U/L. Within 6 weeks of therapy, the pa-
tient was nearly symptom-free. Motor and sensory con-
ductions were still unaffected and needle examination was
normal with no spontaneous activity. Unfortunately, the
patient suffered a relapse in weakness, which was diffuse
and severe. This was attributed to the very rapid tapering
of corticosteroids. Repeat EMG was identical and showed
no neuropathy.
Conclusion
Because of its heterogeneous and multisystemic presenta-
tion with potential pulmonary, cutaneous, and/or neuro-
logical involvement, EGPA can become a diagnostic
challenge with a wide differential. Here, myositis and
eosinophilia raised the possibility of parasitic or bacterial
infections, and viral syndromes. The addition of recent
travels, consumption of bear meat, and minor stool
changes made parasitic infections such as trichinosis a
particularly interesting possibility. Other diagnoses such
as hypereosinophilia syndromes, intoxication, eosino-
philia-myalgia syndrome, idiopathic eosinophilic myositis,
sarcoidosis, or other connective tissue diseases were also
considered. All were excluded based on the clinical infor-
mation, laboratory data, and histological findings. The
particularity of this case was the prominence of myalgia
and weakness as presenting symptoms and the relative
paucity of clinical clues suggesting EGPA.
In our patient, the diagnosis of EGPA was made based
on the criteria for eosinophilia, paranasal sinus abnor-
mality, biopsy-proven eosinophilic necrotizing vasculitis,
and probable late onset asthma suggested by the recent
progressive episodes of wheezing with partial response
to bronchodilators and CS, as well as partial obstruction
reversibility on spirometry.
Clinical findings suggestive of myositis in patients with
a non-EGPA systemic vasculitis may be misleading and
actually represent muscle vasculitis alone rather than
true myositis. For example, a rheumatoid arthritis (RA)
patient with suspected myositis based on hypersignal onMRI STIR sequence only had vasculitis and edema on
muscle biopsy and no evidence of myositis [14]. In a retro-
spective series including 17 systemic vasculitis patients
with muscle biopsy, 9 showed at least probable vasculitis
but only 3 showed necrotic fibers, suggesting a low rate of
myositis [15].
Our case is unusual in that to our knowledge it is the
first to report histologic features of primary inflamma-
tory myopathy, such as phagocytosis of non-necrotic fi-
bers and sarcolemmal overexpression of MHC-1, in a
patient with EGPA presenting with myalgia and weak-
ness. These findings raise the possibility that muscle
involvement in our patient may not be merely the conse-
quence of ischemia caused by middle-sized artery vascu-
litis in muscle and nerve but may actually involve auto-
immunity against muscle fibers. Co-occurrence of systemic
vasculitis and true myositis is known to occur in overlap
syndromes and mixed connective tissue diseases which
generally involve a combination of lupus, scleroderma,
Sjögren syndrome, rheumatoid arthritis and polymyositis,
but these are not commonly associated with EGPA. In
most multisystemic auto-immune diseases, specific organ
involvement can vary significantly for reasons difficult
to establish. Thus, there may not be a characterizable path-
ophysiologic trigger for the occurrence of true myositis in
EGPA.
Another interesting aspect of our case is the surpris-
ingly rapid and significant response to therapy, similar
to other reported EGPA patients presenting with myalgia
with or without myositis [10,12]. In our patient, despite
histological changes typical of denervation, there was no
clinical evidence of neuropathy, perhaps because a path-
ophysiologic threshold had not yet been reached. There-
fore, EGPA presenting with myalgia and weakness may
be an opportunity for early diagnosis which may allow
effective therapy before the onset of clinically significant
vasculitic neuropathy. To assure consistency in evaluat-
ing further cases, we recommend that making the diag-
nosis of EGPA with myositis should require biopsy with
histologic and/or immunohistochemical evidence of muscle
fiber auto-immunity.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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